title: Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation.
abstract: OBJECTIVE
  Patients with acute myelocytic leukemia carrying inversion 16 (inv16) or t(8;21) have a better initial response to high-dose cytarabine than patients without these chromosomal abnormalities. They presently do not undergo transplantation in first remission (CR1), but there is concern about late relapses.
  
  
  METHODS
  From 1990 to 2004, 325 adult patients received transplantations in CR1 (159 patients with inv16 and 166 patients with t(8;21), including 35 and 60 patients, respectively, with additional chromosomal abnormalities). Genoidentical allografts were performed in 64 patients with inv16 and 81 patients with t(8;21), and autografts were performed in 95 patients with inv16 and 85 patients with t(8;21).
  
  
  RESULTS
  In patients with inv16, after allogeneic and autologous transplantation, the 5-year leukemia-free survival (LFS) rates were 59% and 66% (P = .5), the relapse incidence (RI) rates were 27% and 32% (P = .45), and the transplantation-related mortality (TRM) rates were 14% and 2% (P = .003), respectively. Female patients had a lower RI and a higher LFS. Additional chromosomal abnormalities, compared with no additional abnormalities, were associated with lower RI rate (12% v 34%, respectively; P = .01) and higher 5-year LFS rate (78% v 59%, respectively; P = .04). In patients with t(8;21), after allogeneic and autologous transplantation, the 5-year LFS rates were 60% and 66% (P = .69), the RI rates were 15% and 28% (P = .03), and the TRM rates were 24% and 6% (P = .003), respectively. Younger age and a lower WBC count at diagnosis were associated with a lower TRM and a better LFS. The TRM was lower and the RI was higher in patients with autologous transplantations versus allogeneic transplantations.
  
  
  CONCLUSIONS
  Both autologous and allogeneic transplantation resulted in similar outcomes.
authors.affiliation: Department of Hematology, Hopital Saint-Antoine and Université Pierre et Marie Curie UPMC, 184 Rue du Faubourg Saint-Antoine, Cedex 12 Paris, France. norbert-claude.gorin@sat.aphp.fr
authors.forename: Norbert-Claude
authors.initials: NC
authors.lastname: Gorin
authors.forename: Myriam
authors.initials: M
authors.lastname: Labopin
authors.forename: Francesco
authors.initials: F
authors.lastname: Frassoni
authors.forename: Noel
authors.initials: N
authors.lastname: Milpied
authors.forename: Michel
authors.initials: M
authors.lastname: Attal
authors.forename: Didier
authors.initials: D
authors.lastname: Blaise
authors.forename: Giovanna
authors.initials: G
authors.lastname: Meloni
authors.forename: Anna P
authors.initials: AP
authors.lastname: Iori
authors.forename: Mauricette
authors.initials: M
authors.lastname: Michallet
authors.forename: Roel
authors.initials: R
authors.lastname: Willemze
authors.forename: Eric
authors.initials: E
authors.lastname: Deconninck
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Harousseau
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Polge
authors.forename: Vanderson
authors.initials: V
authors.lastname: Rocha
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D016009:Chi-Square Distribution; D007446:Chromosome Inversion; D002885:Chromosomes, Human, Pair 16; D002891:Chromosomes, Human, Pair 21; D002898:Chromosomes, Human, Pair 8; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D018709:Statistics, Nonparametric; D011795:Surveys and Questionnaires; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D016896:Treatment Outcome